Market Cap (In USD)
512.41 Million
Revenue (In USD)
-
Net Income (In USD)
-29.06 Million
Avg. Volume
2.04 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.27-4.675
- PE
- -11.28
- EPS
- -0.47
- Beta Value
- 1.014
- ISIN
- US89532M1018
- CUSIP
- 89532M101
- CIK
- 1563880
- Shares
- 96682200.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Jennifer L. Good
- Employee Count
- -
- Website
- https://www.trevitherapeutics.com
- Ipo Date
- 2019-05-07
- Details
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
More Stocks
-
CRWD
-
HTIBPHealthcare Trust, Inc.
HTIBP
-
PURSHOTTAMPurshottam Investofin Limited
PURSHOTTAM
-
1818
-
ACLIFAccelleron Industries AG
ACLIF
-
003520Yungjin Pharm. Co., Ltd.
003520
-
2441
-
BHAC